<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602508</url>
  </required_header>
  <id_info>
    <org_study_id>178-MA-3147</org_study_id>
    <nct_id>NCT03602508</nct_id>
  </id_info>
  <brief_title>Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania</brief_title>
  <official_title>Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Singapore Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to descriptively evaluate the persistence among adults treated
      with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.

      This study will also assess the persistence to the overall Overactive bladder (OAB)
      treatments of a patient, regardless of treatment discontinuation or switch to other OAB
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is entirely descriptive using secondary medical claim and pharmacy prescription
      data. No formal comparisons between users of mirabegron and antimuscarinic will be made.
      Furthermore, no a priori hypothesis testing is intended.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Actual">September 13, 2019</completion_date>
  <primary_completion_date type="Actual">September 13, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients persistence to the index medication</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Persistence to the index medication (i.e. mirabegron; solifenacin; darifenacin; imidafenacin; tolterodine; oxybutynin; trospium; fesoterodine; propiverine) is defined as the time to discontinuation during the 1 year post-index period. Days with the index medication for each patient will be calculated as the sum of days of supply per prescription.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients persistence to the overall Overactive Bladder (OAB) treatment regardless of treatment switching to other OAB medications</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to discontinuation of the overall OAB treatment during the one-year post-index period (persistence) is defined as days with the index medication (i.e. mirabegron; solifenacin; darifenacin; imidafenacin; tolterodine; oxybutynin; trospium; fesoterodine; propiverine) for each patient and days' supply of any OAB medication will be added up until the grace period exceeds 30 days.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5589</enrollment>
  <condition>Overactive Bladder (OAB)</condition>
  <arm_group>
    <arm_group_label>mirabegron</arm_group_label>
    <description>Patients on mirabegron as prescribed by a physician in routine clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antimuscarinics</arm_group_label>
    <description>Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>mirabegron</arm_group_label>
    <other_name>YM178</other_name>
    <other_name>Betmiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
    <other_name>YM905</other_name>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imidafenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolterodine</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxybutynin</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trospium</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propiverine</intervention_name>
    <description>oral</description>
    <arm_group_label>antimuscarinics</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient (aged ≥18 years; except for Taiwan ≥20 years old) with overactive bladder who
        received pharmacological treatment between 1st July 2015 and 29th February 2016.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a new prescription of the index medication within the index period;

          -  Patient received orally administered monotherapy for OAB on index date.

        Exclusion Criteria:

          -  Patient with prior dispensing record of the index medication during the pre-index
             period;

          -  Patient received onabotulinumtoxin A and/or surgical intervention as part of the OAB
             treatment between the pre index and post-index period;

          -  Patient diagnosed with stress incontinence (International Classification of
             Diseases-10 (ICD-10) N39.3 or equivalent) or had dispensing record of medication for
             stress incontinence (duloxetine) before index date;

          -  Patient with urinary tract infection (ICD-10 N30.0 or equivalent) (for National Health
             Insurance Research Database (NHIRD) and Health Insurance Review and Assessment (HIRA)
             database) or a co-prescription of any antibiotics (for NostraData) on index date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Singapore Pte. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site AU10000</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82001</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>darifenacin</keyword>
  <keyword>fesoterodine</keyword>
  <keyword>trospium</keyword>
  <keyword>solifenacin</keyword>
  <keyword>oxybutynin</keyword>
  <keyword>tolterodine</keyword>
  <keyword>Betmiga</keyword>
  <keyword>YM178</keyword>
  <keyword>mirabegron</keyword>
  <keyword>Overactive bladder</keyword>
  <keyword>propiverine</keyword>
  <keyword>antimuscarinics</keyword>
  <keyword>OAB</keyword>
  <keyword>imidafenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Fesoterodine</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Darifenacin</mesh_term>
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Phase 1 trial in healthy volunteers, phase 1 trial in volunteers with renal/hepatic impairment or non-interventional (observational) trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

